Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1789 1
1792 2
1799 1
1918 1
1919 1
1923 1
1924 3
1926 1
1929 1
1930 7
1931 4
1932 4
1934 2
1935 1
1936 1
1938 1
1945 1
1946 4
1947 4
1948 2
1949 3
1950 4
1952 1
1953 1
1954 3
1956 2
1957 1
1958 1
1959 2
1960 1
1961 1
1962 2
1963 2
1964 1
1965 7
1966 4
1967 2
1968 3
1969 9
1970 2
1971 1
1972 2
1973 4
1975 7
1976 1
1977 4
1978 5
1979 4
1980 14
1981 9
1982 6
1983 10
1984 9
1985 8
1986 12
1987 15
1988 18
1989 20
1990 19
1991 29
1992 32
1993 18
1994 30
1995 33
1996 26
1997 31
1998 29
1999 23
2000 41
2001 36
2002 37
2003 50
2004 69
2005 70
2006 76
2007 78
2008 97
2009 113
2010 102
2011 97
2012 100
2013 131
2014 124
2015 114
2016 109
2017 142
2018 165
2019 137
2020 164
2021 190
2022 187
2023 155
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

2,841 results

Results by year

Filters applied: . Clear all
Page 1
Management of TKI-resistant chronic phase CML.
Hughes TP, Shanmuganathan N. Hughes TP, et al. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):129-137. doi: 10.1182/hematology.2022000328. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485117 Free PMC article. Review.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. Réa D, et al. Among authors: hughes tp. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. Blood. 2021. PMID: 34407542 Free PMC article. Clinical Trial.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: hughes tp. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.
Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Schalck A, et al. Among authors: hughes tg. Cancer Discov. 2022 Oct 5;12(10):2330-2349. doi: 10.1158/2159-8290.CD-21-1248. Cancer Discov. 2022. PMID: 35849783 Free PMC article.
Regulation of alternative polyadenylation by the C2H2-zinc-finger protein Sp1.
Song J, Nabeel-Shah S, Pu S, Lee H, Braunschweig U, Ni Z, Ahmed N, Marcon E, Zhong G, Ray D, Ha KCH, Guo X, Zhang Z, Hughes TR, Blencowe BJ, Greenblatt JF. Song J, et al. Among authors: hughes tr. Mol Cell. 2022 Sep 1;82(17):3135-3150.e9. doi: 10.1016/j.molcel.2022.06.031. Epub 2022 Jul 31. Mol Cell. 2022. PMID: 35914531 Free article.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Among authors: hughes tp. Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414482 Free PMC article. Clinical Trial.
The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts.
Friščić J, Böttcher M, Reinwald C, Bruns H, Wirth B, Popp SJ, Walker KI, Ackermann JA, Chen X, Turner J, Zhu H, Seyler L, Euler M, Kirchner P, Krüger R, Ekici AB, Major T, Aust O, Weidner D, Fischer A, Andes FT, Stanojevic Z, Trajkovic V, Herrmann M, Korb-Pap A, Wank I, Hess A, Winter J, Wixler V, Distler J, Steiner G, Kiener HP, Frey B, Kling L, Raza K, Frey S, Kleyer A, Bäuerle T, Hughes TR, Grüneboom A, Steffen U, Krönke G, Croft AP, Filer A, Köhl J, Klein K, Buckley CD, Schett G, Mougiakakos D, Hoffmann MH. Friščić J, et al. Among authors: hughes tr. Immunity. 2021 May 11;54(5):1002-1021.e10. doi: 10.1016/j.immuni.2021.03.003. Epub 2021 Mar 23. Immunity. 2021. PMID: 33761330 Free article.
2,841 results